الفهرس 
EPIDEMIOLOGYOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Breast cancer is the most common malignancy in women,
accounting for 27% of all female cancers; also is
responsible for 15% of cancer deaths in women, making it the
number-two cause of cancer death.
In females, breast and liver cancer occupied the top ranks
accounting for around 45% of all cancers in females in Egypt.
Metastatic disease is found at presentation in 5% to 10%
of patients with breast cancer. The most common sites of
distant metastasis are the lungs, liver, lymph nodes, and bone.
Treatment for systemic disease is palliative in intent.
Goals of treatment include improving quality of life and
prolongation of life. Treatment of metastatic breast cancer will
usually involve hormone therapy and/or chemotherapy with or
without targeted agents. Radiation therapy and/or surgery may
be indicated for patients with limited symptomatic metastases.
The median survival for patients with metastatic (stage
IV) breast cancer is 18 to 24 months, but range extends from
only a few months to many years.
Anthracycline-based chemotherapy in combination with
cyclophosphamide and/or taxane is one of the commonly
prescribed regimens for anthracycline-naïve stage IV breast
cancer while Single-agent taxanes are an effective option in metastatic patients who were treated with only anthracyclinebased
adjuvant therapy.
In our retrospective analysis of HER2 negative
metastatic breast cancer patients, 52 patients were eligible and
patients baseline characters were analysed where mean age was
48.7 years , 25% died, 6% lost follow up, 27% were alive.
Median overall survival 30 months, median progression
free survival was 5 monthes. There was no significant
correlation between patients general characters and survival
functions, only patients who became metastatic after failure of
adjuvant treatment had better overall survival than those
metastatic at presentation.
Anthracycline based regimens were not superior to non
anthracycline containing regimens used treating patients who
were anthracycline-naïve as there was statistically significant
difference regarding overall survival, progression free survival
and response.
On the other hand, patients who became metastatic after
failure of adjuvant chemotherapy, taxane based regimens had
improves overall survival than non taxane regimens but no
difference as regard response and progression free survival.